Cerus Corp posts Q2 2026 earnings in line with expectations and lifts revenue outlook

Cerus Corporation reported second‑quarter 2026 earnings that met consensus estimates, posting earnings per share of $0.01 and revenue of $63.3 million, slightly above analysts' $62.9 million forecast. Product revenue rose 10% to $57.4 million, driving a 16% year‑over‑year increase in first‑half revenue. The company raised the low end of its 2026 product‑revenue guidance to $229‑$231 million and increased its INTERCEPT fibrinogen complex (IFC) revenue outlook to $23‑$25 million after a 40% surge. Cerus also refinanced debt, cutting a term loan by $30 million and aiming to reduce annual interest expense by up to $3.5 million. Adjusted EBITDA remained positive for the ninth consecutive quarter, and management said a path to GAAP profitability is in place. The firm submitted an INT200 platelet PMA to the FDA and expects possible approval in early 2027, while Phase III INTERCEPT red‑blood‑cell trial results are slated for the fourth quarter. Additionally, Cerus expanded its BARDA contract by nearly $22 million to support U.S. regulatory activities.